

**ELIZABETH IJEOMA ONYEMELUKWE GARNER**

LinkedIn: <https://www.linkedin.com/in/elizabethgarnermd/>

**CURRENT ROLE**

Chief Medical Officer  
ObsEva, SA.  
Boston, MA/Geneva, Switzerland

**EDUCATION**

**Medical:**

1994 M.D. Harvard Medical School, Boston, MA  
1994 M.P.H. Harvard School of Public Health, Boston, MA

**Undergraduate:**

1989 A.B. Mount Holyoke College, South Hadley, MA-Magna Cum Laude/Phi Beta Kappa

**POSTDOCTORAL TRAINING**

2000-2003 Fellow in Gynecologic Oncology, Brigham and Women's Hospital, Boston, MA  
1996-1999 Resident in Obstetrics and Gynecology, Brigham and Women's Hospital/Massachusetts General Hospital, Boston, MA  
1995-1996 Intern in Obstetrics and Gynecology, Brigham and Women's Hospital/Massachusetts General Hospital, Boston, MA  
1994-1995 Intern in Internal Medicine, Massachusetts General Hospital, Boston, MA

**ACADEMIC APPOINTMENTS**

2005-2007 Assistant Professor in Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA  
2003-2005 Instructor in Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, MA  
2000-2003 Clinical Fellow in Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA  
1999-2000 Assistant (Instructor) in Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA  
1995-1999 Clinical Fellow in Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA  
1994-1995 Clinical Fellow in Internal Medicine, Harvard Medical School, Boston, MA

**PROFESSIONAL ROLES**

2019-Present **OBSEVA, SA**  
**CHIEF MEDICAL OFFICER**

- Active contributor on key company strategic leadership and governance as member of Senior Executive Team
- Represent company to investors, Key Opinion Leaders, advocacy groups and other key stakeholders
- Lead clinical development vision and strategy for the company's candidate products
- Plan and design overall clinical development plan and clinical trials for company's active and pipeline drug candidates
- Oversee all clinical operations
- Provide medical oversight of early and late-stage clinical programs

- **Oversee analysis and interpretation of clinical trial data and the reporting of clinical trial results**
- **Clinical lead for company's worldwide regulatory strategy**
- **Oversee safety, pharmacovigilance and Medical Information strategy and operations**

2014-2019

**AGILE THERAPEUTICS, INC.**  
**CHIEF MEDICAL OFFICER,**

- **Active contributor on key company strategic leadership and governance as member of Senior Executive Team**
- **Core executive management team member for the company's Initial Public Offering in 2014**
- **Represented company to investors, Key Opinion Leaders, advocacy groups, and other key stakeholders**

2012-2014

**MYRIAD GENETICS LABORATORIES**

**VICE PRESIDENT Medical Affairs, Women's Health/Preventive Care**

- **Developed and executed the Medical Affairs strategy for the Preventive Care/Women's Health Business Unit**
- **Managed Medical Affairs budget**
- **Provided medical and scientific input and support to marketing regarding positioning strategy**
- **Participated in due diligence activities around women's health/preventive care new product opportunities**
- **Oversaw team of 27 field-based Regional Medical Specialists and managers in women's health**

2011-2012

**ABBOTT LABORATORIES**

**SENIOR MEDICAL DIRECTOR, Women's Health**

- **Clinical Lead, Endometriosis Program**
  - **Managed clinical aspects of the global Phase 3 development program in endometriosis, including protocol development, preparation of regulatory documents, safety and risk management plans, operations (site and vendor selection), and medical affairs**
  - **Led efforts in identification of supplemental research projects for endometriosis program**

2007-2011

**MERCK RESEARCH LABORATORIES**

**DIRECTOR, Vaccines (2010-2011)**

- **Clinical Lead, and Product Development Team Chair, Next Generation Human Papillomavirus (HPV) Vaccine (Gardasil®9) Program**
  - **Led cross-functional Product Development Team in formulation of strategy for Next General HPV Vaccine program with respect to scientific, regulatory, global access, medical affairs strategy**
  - **Supervised team preparation for regulatory filings**

**ASSOCIATE DIRECTOR, Vaccines (2007-2010)**

- **Clinical Trials Team Leadership**
- **FDA Filings:**
  - **Prepared comprehensive Clinical Study Reports and other NDA documents.**
  - **Supervision of writing and preparation of key FDA and EU Regulatory filings for GARDASIL™ (HPV Vaccine) Vaccine studies.**
  - **Actively participated in preparation of responses to regulatory questions and label negotiations.**

- **Clinical trials:**
  - **Development of clinical development strategic plan for demonstration of GARDASIL™ efficacy against HPV-related head and neck cancer**
  - **Developed clinical trial design for evaluation of novel adjuvant in next generation HPV Vaccine Program**
  - **Clinical monitoring of active clinical trials**
- **Developing world and emerging markets**
  - **Formulated clinical development plan for HPV vaccine developing world introduction**
  - **Developed clinical protocol for safety/efficacy study in Sub-Saharan Africa**
  - **Participated in development of developing world and emerging market target product profiles for novel vaccine candidate**

#### **CORPORATE BOARD POSITIONS**

- 2021- Board of Directors, Sermonix Pharmaceuticals  
2020- Board of Directors, Pharm-Olam International (mid-size global CRO)  
(Regulatory/Compliance Committee)  
2019- Board of Directors, Kezar Life Sciences (KZR) (Audit and Clinical/Regulatory  
Strategy Committee)

#### **NON-PROFIT BOARD/COMMITTEE MEMBERSHIPS**

- 2021- Chair, Drug Information Association (DIA) Patient Advisory Council  
2019- Board of Directors, DIA (Audit Committee)  
2018- Harvard Medical School Alumni Council  
2018- Board of Directors, CorStone <https://corstone.org/> (Secretary)  
2017- Board of Directors, American Medical Women's Association (AMWA) (Treasurer,  
Executive and Finance Committees, Strategic Planning Implementation Committee,  
Cervical Cancer Task Force)  
2009-2014 Mount Holyoke College Board of Trustees (Audit, Nominating/Governance,  
Development Committees)

#### **MEMBERSHIPS/PROFESSIONAL SOCIETY/COMMITTEE ASSIGNMENTS**

American Medical Women's Association (AMWA)  
Drug Information Association (DIA)  
Executive Women of New Jersey (EWNJ)  
Society for Maternal Fetal Medicine (SMFM)  
Healthcare Businesswomen's Association (HBA)

#### **LICENSURE AND CERTIFICATION\***

- \*Active Pennsylvania Medical License  
2006 Diplomat, American Board of Obstetrics and Gynecology, subspecialist in Gynecologic  
Oncology  
2004 Diplomat, American Board of Obstetrics and Gynecology

#### **AWARDS AND HONORS**

- 2019 PharmaVOICE 100 Most Inspiring People in the life sciences industry  
2018 Honoree, Executive Women of New Jersey Bi-Annual Salute to Policy Makers  
2012 Abbott Labs Excellence Award for significant contribution to Investigator Meeting Initiative

- 2011 Abbott Labs Excellence Award for significant contributions to FDA background package and supporting documents
- 2009 Merck Special Achievement Award for contributions to project on evaluation of novel pathogen targets in emerging markets
- 2009 Merck Recognition for outstanding contributions to due diligence processes for successful licensing transaction
- 2009 "Appreciation at Merck" Award
- 2010 Identified as Key Talent at Merck

**PUBLICATIONS (Limited to 2010 forward)**

1. Nelson AL, Kaunitz AM, Kroll R, Simon J, Poindexter AN, Castano PM, Ackerman, RT, Flood L, Chiodo JA, *Garner EI*. Efficacy, Safety, and Tolerability of a Levonorgestrel/Ethinyl Estradiol Transdermal Delivery System: Phase 3 Clinical Trial Results. *Contraception*. 2021, 103(3):137-43.
2. Griesinger G, Blockeel C, Pierzynski P, Tournaye H, Visnova H, Humberstone A, Terrill P, *Garner E*, Donnez J, Loumaye E. Effect of the Oxytocin Receptor Antagonist Nolasiban on Pregnancy Rates in Women Undergoing Embryo Transfer Following IVF: Analysis of Three Randomised Clinical Trials. *Human Reproduction*. 2021, 36(4):1007-20.
3. Edelman A, Trussell J, Aiken AR, Portman DJ, Chiodo JA, *Garner EI*. The Emerging Role of Obesity in Short-Acting Hormonal Contraceptive Effectiveness. *Contraception*. 2018, 97(5):371-7.
4. Mugo N, Ansah NA, Marino D, Saah A, *Garner EI*. Evaluation of Safety and Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa. *Hum Vaccin Immunother*. 2015, 11(6):1323-30.
5. Carr B, Dmowski WP, O'Brien C, Jiang P, Burke J, Jimenez R, *Garner E*, Chwalisz K. Elagolix, an Oral Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density. *Reprod Sci*. November 2014, 21(11):1341-51.
6. Diamond MP, Carr B, Dmowski WP, Koltun W, O'Brien C, Jiang P, Jimenez R, *Garner E*, Chwalisz K. Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. *Reprod Sci*. March 2014, 21(3):363-71.
7. Goldstone SE, Jessen H, Palefsky JM, Giuliano AR, Moreira ED Jr, Vardas E, Aranda C, Hillman RJ, Ferris DG, Coutlee F, Marshall JB, Vuocolo S, Haupt RM, Guris D, *Garner E*. Quadrivalent HPV Vaccine Efficacy Against Disease Related to Vaccine and Non-Vaccine HPV Types in Males. *Vaccine*. August 2013, 31(37):3849-55.
8. Clark LR, Myers ER, Huh W, Joura EA, Paavenon J, Perez G, James MK, Sings HL, Haupt RM, Saah AJ, *Garner EI*. Clinical Trial Experience with Prophylactic Human Papillomavirus 6/11/16/18 Vaccine in Young Black Women. *Journal Adolesc Health*. March 2013, 52(3):322-9.
9. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Vardas E, Aranda C, Jessen H, Ferris DG, Coutlee F, Marshall JB, Vuocolo S, Haupt RM, Guris D, *Garner EI*. Immunogenicity of the quadrivalent (type 6/11/16/18) human papillomavirus vaccine in males 16 to 26 years old. *Clin Vaccine Immunol*. February 2012, 19(2):261-7.
10. Palefsky J, Giuliano AR, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Hillman RJ, Chang Y, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, *Garner EI*. HPV Vaccine Efficacy against Anal HPV 6/11/16/18 Infection and Anal Intraepithelial Neoplasia. *NEJM*. October 2011, 365(17):1576-85.
11. Moreira ED, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H, Hillman RJ, Ferris D, Coutlee F, Vardas E, Marshall JB, Vuocolo S, Haupt RM, Guris D, *Garner EI*. Safety and Reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 Viral-Like Particle Vaccine in Older Adolescents and Young Adults. *Hum Vaccin*. July 2011, 7(7):768-75.
12. Brown DR, Garland SM, Ferris DG, Joura E, Steven M, James M, Radley D, Vuocolo S, *Garner EI*, Haupt RM, Bryan JT. The Humoral Response to Gardasil over Four Years as Defined by Total IgG and Competitive Luminex Immunoassay. *Hum Vaccin*. February 2011, 7(2):230-8.
13. Goldstone S, Palefsky J, Giuliano AR, Moreira ED, Aranda C, Jessen H, Hillman RJ, Ferris DG, Coutlee F, Liaw KL, Marshall JB, Zhang X, Vuocolo S, Barr E, Haupt RM, Guris D, *Garner EI*.

- Prevalence of and Risk Factors for Human Papillomavirus Infection Among HIV-Seronegative Men Who Have Sex with Men. *JID*. January 2011, 203(1):66-74.
14. Vardas E, Giuliano AR, Goldstone S, Palefsky JM, Moreira ED Jr, Penny ME, Aranda C, Jessen H, Moi H, Ferris DG, Liaw KL, Marshall JB, Vuocolo S, Barr E, Haupt RM, *Garner EI*, Guris D. External Genital Human Papillomavirus Prevalence and Associated Factors Among Heterosexual Men on 5 Continents. *JID*. January 2011, 203(1):58-65.
  15. Gao Z, Litkouhi B, Berkowitz RS, *Garner EI*. C-Terminus of Clostridium Perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin. *Clinical Cancer Res*. December 2011, 17(5):1065-74.
  16. Ault KA, Jaura EA, Kjaer SK, Iversen OE, Wheeler CM, Perez G, Brown DR, Koutsky LA, Garland SM, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Majewski S, Muñoz N, Sings HL, Harkins K, Rutkowski MA, Haupt RM, *Garner EI*. Adenocarcinoma in Situ and Associated Human Papillomavirus Type Distribution Observed in Two Clinical Trials of a Quadrivalent Human Papillomavirus Vaccine. *Int J Cancer*. March 2011, 128(6):1344-53.
  17. *Garner EI*. A Case Study: Lessons learned from Human Papillomavirus Vaccine Development: Approval of a Vaccine for Use in Children and Young Adolescents for Prevention of an Adult Disease. *J Acquir Immune Defic Syndr*. July 2010, 54 Suppl 1:S50-52.
  18. Chapman E, Venkat P, Ko E, Orezza JP, Del Carmen M, *Garner EI*. Use of Multimedia as an Educational Tool to Improve Human Papillomavirus Vaccine Acceptability-A Pilot Study. *Gynecol Oncol*. August 2010, 118(2):103-7.
  19. Reisinger KS, Block SL, Collins-Ogle M, Marchant C, Catlett M, Radley D, Sings HL, Haupt RM, *Garner EI*. Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly with Menactra and Adacel. *Pediatrics*. June 2010, 125(6):1142-51.
  20. Jarboe EA, Venkat P, Hirsch MS, Cibas ES, Crum CP, *Garner EI*. A Weakly Positive Human Papillomavirus Hybrid Capture II Result Correlates with a Significantly Lower Risk of Cervical Intraepithelial Neoplasia 2,3 After Atypical Squamous Cells of Undetermined Significance Cytology. *J Low Genit Tract Dis*. July 2010, 14(3):174-7.